[HTML] nih.gov

[HTML][HTML] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K Al-Farsi, T Nagy… - …, 2010 - ncbi.nlm.nih.gov
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …
被引用次数：34 相关文章

[引用][C] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N PUIG, M PINTILIE, T SESHADRI… - Haematologica …, 2010 - pascal-francis.inist.fr
Different response to salvage chemotherapy but similar post-transplant outcomes in
patients with relapsed and refractory Hodgkin's lymphoma CNRS Inist Pascal-Francis …
[PDF] academia.edu

[PDF][PDF] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K al-Farsi, T Nagy… - …, 2010 - academia.edu
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K Al-Farsi… - …, 2010 - squ.elsevierpure.com
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …
[HTML] haematologica.org

[HTML][HTML] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K al-Farsi, T Nagy… - …, 2010 - haematologica.org
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …
[PDF] researchgate.net

[PDF][PDF] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K al-Farsi, T Nagy… - …, 2010 - researchgate.net
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K Al-Farsi… - …, 2010 - pubmed.ncbi.nlm.nih.gov
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.

N Puig, M Pintilie, T Seshadri, K Al-Farsi, T Nagy… - …, 2010 - europepmc.org
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …
[PDF] academia.edu

[PDF][PDF] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

N Puig, M Pintilie, T Seshadri, K al-Farsi, T Nagy… - …, 2010 - academia.edu
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.

N Puig, M Pintilie, T Seshadri, K Al-Farsi, T Nagy… - …, 2010 - europepmc.org
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …